NASDAQ:SXTC - Nasdaq - VGG2161P1403 - Common Stock
CHINA SXT PHARMACEUTICALS IN
NASDAQ:SXTC (1/17/2025, 8:00:01 PM)
After market: 0.41 0 (-0.1%)0.4104
+0 (+0.1%)
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -13.4% | ||
ROE | -22.24% | ||
Debt/Equity | 0.04 |
Which stocks are moving after the closing bell on Monday?
Curious about the stocks that are showing activity after the closing bell on Monday?
Jiangsu, China, , Oct. 07, 2024 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (“SXTC” or the “Company”), (NASDAQ: SXTC) announced today that on...
China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). The company is headquartered in Taizhou, Jiangsu and currently employs 75 full-time employees. The company went IPO on 2019-01-04. The firm develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The firm sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.
CHINA SXT PHARMACEUTICALS IN
178 Taidong Road North
Taizhou JIANGSU 225300 CN
CEO: Feng Zhou
Employees: 75
Company Website: http://www.sxtchina.com/
Investor Relations: http://www.sxtchina.com/aqresults
Phone: 8652386298290
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 71.36 | 688.94B | ||
JNJ | JOHNSON & JOHNSON | 14.36 | 353.99B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 26.86 | 349.49B | ||
MRK | MERCK & CO. INC. | 16.46 | 247.70B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 17.48 | 206.53B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.07 | 194.99B | ||
PFE | PFIZER INC | 10.19 | 149.04B | ||
SNY | SANOFI-ADR | 12.32 | 127.21B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.11 | 114.17B | ||
ZTS | ZOETIS INC | 28.8 | 74.84B | ||
GSK | GSK PLC-SPON ADR | 8.21 | 68.21B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.53 | 40.96B |